Trust Co. of Vermont decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 20.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 323,516 shares of the biopharmaceutical company's stock after selling 84,607 shares during the quarter. Trust Co. of Vermont's holdings in Pfizer were worth $8,583,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of PFE. Swiss National Bank increased its stake in Pfizer by 0.6% in the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock valued at $486,762,000 after buying an additional 100,900 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after acquiring an additional 12,864,343 shares during the last quarter. Empowered Funds LLC increased its position in shares of Pfizer by 80.9% in the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock valued at $14,709,000 after acquiring an additional 227,349 shares during the last quarter. Addison Advisors LLC raised its holdings in Pfizer by 394.2% during the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock worth $1,512,000 after acquiring an additional 41,668 shares in the last quarter. Finally, KBC Group NV grew its stake in Pfizer by 26.0% in the third quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock valued at $89,872,000 after purchasing an additional 639,985 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other news, Director Scott Gottlieb acquired 1,000 shares of the firm's stock in a transaction dated Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is currently owned by insiders.
Pfizer Price Performance
NYSE:PFE traded down $0.19 during trading hours on Friday, hitting $26.30. The company's stock had a trading volume of 35,146,711 shares, compared to its average volume of 35,869,448. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a fifty day simple moving average of $26.08 and a 200-day simple moving average of $27.99.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same quarter last year, the business posted ($0.17) earnings per share. The company's quarterly revenue was up 31.2% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.
Pfizer Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.54%. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio (DPR) is presently 227.03%.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on PFE shares. Bank of America reissued a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Evercore ISI upgraded Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Finally, Truist Financial dropped their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $32.00.
Read Our Latest Analysis on Pfizer
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report